A series of in vitro studies for a novel class of antimicrobials created by Lakewood-Amedex, Inc., recently found that they effectively kill strains of multi-drug resistant Mycobacterium tuberculosis (TB) in just 15 minutes.
A team of researchers from Southern Research in Birmingham, Alabama conducted the studies using Lakewood-Amedex's bisphosphocins antimicrobials against MDR-TB strains CSU 39 and CSU 41, and wild type strain H37Rv. Both of the CSU strains are resistant to more than six antibiotic classes.
The new research findings support previous experiments showing that bisphosphocin Nu-3 effectively kills multi-drug resistant bacteria.
Approximately a third of the world's population has chronic lung infection TB as a result of being infected with Mycobacterium tuberculosis. The infection is becoming increasingly resistant to the current TB treatments. The strength of the resistant strains has become a serious health concern for medical and health communities, as there is no longer any effective cure for the illness.
The new study demonstrates that this new class of antimicrobials has immense potential for use in fighting TB.